| 10.03 -0.2 (-1.96%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.07 | 1-year : | 14.5 |
| Resists | First : | 11.19 | Second : | 12.42 |
| Pivot price | 10.07 |
|||
| Supports | First : | 9.21 | Second : | 7.66 |
| MAs | MA(5) : | 10.35 |
MA(20) : | 10.17 |
| MA(100) : | 12.93 |
MA(250) : | 13.14  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 65.2 |
D(3) : | 73.2 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 26.95 | Low : | 6.38 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CRVS ] has closed above bottom band by 46.9%. Bollinger Bands are 40% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.2 - 10.28 | 10.28 - 10.34 |
| Low: | 9.61 - 9.7 | 9.7 - 9.76 |
| Close: | 9.9 - 10.04 | 10.04 - 10.14 |
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Thu, 29 Oct 2026
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026 - Yahoo Finance
Wed, 28 Oct 2026
CRVS Q3'26 Earnings: EPS estimate is (0.19) USD - TradingView
Fri, 23 Oct 2026
Corvus Pharmaceuticals, Inc. Estimates – NASDAQ:CRVS - TradingView
Mon, 12 Oct 2026
Corvus Pharma Q2 2026 Earnings Call Transcript - Corvus Pharmaceuticals (NASDAQ:CRVS) - Benzinga
Fri, 25 Sep 2026
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In? - Yahoo Finance
Thu, 27 Aug 2026
Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 84 (M) |
| Shares Float | 73 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 85.8 (%) |
| Shares Short | 17,800 (K) |
| Shares Short P.Month | 19,020 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.7 % |
| Return on Equity (ttm) | -35.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -16.17 |
| PEG Ratio | 0 |
| Price to Book value | 3.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|